TY  - GEN
AU  - Press,Oliver W
AU  - Unger,Joseph M
AU  - Rimsza,Lisa M
AU  - Friedberg,Jonathan W
AU  - LeBlanc,Michael
AU  - Czuczman,Myron S
AU  - Kaminski,Mark
AU  - Braziel,Rita M
AU  - Spier,Catherine
AU  - Gopal,Ajay K
AU  - Maloney,David G
AU  - Cheson,Bruce D
AU  - Dakhil,Shaker R
AU  - Miller,Thomas P
AU  - Fisher,Richard I
TI  - A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab
SN  - 1557-3265
PY  - 2014///0714
KW  - Adult
KW  - Aged, 80 and over
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Clinical Trials, Phase III as Topic
KW  - Cyclophosphamide
KW  - Disease-Free Survival
KW  - Doxorubicin
KW  - Hemoglobins
KW  - metabolism
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Lymph Nodes
KW  - pathology
KW  - Lymphoma, Follicular
KW  - blood
KW  - Middle Aged
KW  - Multivariate Analysis
KW  - Organ Size
KW  - Prednisone
KW  - Prognosis
KW  - Proportional Hazards Models
KW  - Rituximab
KW  - Vincristine
KW  - Young Adult
KW  - beta 2-Microglobulin
N1  - Publication Type: Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/1078-0432.CCR-13-1120
ER  -